Roctavian (valoctocogene roxaparvovec-rvox)

Medical Administration – Intravenous

Diagnosis considered for coverage:
  • Hemophilia A: Indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
Coverage Criteria:

For diagnosis of Hemophilia A:

  • Diagnosis of severe Hemophilia A, AND
  • Factor VIII (FVIII) assay baseline level of less than or equal to 1 IU/dL, AND
  • Patient is 18 years of age or older, AND
  • Patient does not have pre-existing immunity to the AAV5 capsid as detected by the FDA-approved companion diagnostic test, AND
  • Patient does not have a history of inhibitors based on results from a modified Nijmegen Bethesda assay of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least 1 week apart within the past 12 months, AND
  • Treatment logs including both factor infusions and bleeding episodes confirming BOTH of the following:
    • Patient has been on prophylactic FVIII replacement therapy for at least 12 months
    • Patient has been treated/exposed to FVIII concentrates for a minimum 150 exposure days (EDs), AND
  • One of the following:
    • Patient does not exhibit significant liver dysfunction as defined by abnormal elevation of ONE of the following:
      • alanine transaminase (ALT) greater than 1.25 times the upper limit of normal
      • aspartate aminotransferase (AST) greater than 1.25 times the upper limit of normal
      • gamma-glutamyl transferase (GGT) greater than 1.25 times the upper limit of normal 
      • alkaline phosphatase (ALP) greater than 1.25 times the upper limit of normal
      • bilirubin greater than 1.25 times the upper limit of normal
      • international normalized ratio (INR) greater than or equal to 1.4, OR
    • Patient has had a consultation with a hepatologist to assess eligibility for Roctavian, AND
  • Patient does not have an active infection or any immunosuppressive disorder, AND
  • Patient has never received valoctocogene roxaparvovec treatment in their lifetime, AND
  • Prescribed by a hematologist affiliated with a comprehensive hemophilia treatment center (HTC), AND
  • Prescriber attests that the patient has been counseled and has agreed to adhere to post-treatment monitoring and follow-ups with their hematologist and HTC
Dosing:
  • The recommended dose of ROCTAVIAN is 6 × 1013 vector genomes per kilogram (vg/kg) body weight, administered as a single intravenous infusion. ROCTAVIAN is administered using an infusion pump at a rate of 1 mL/min, which can be increased every 30 minutes by 1 mL/min up to a maximum rate of 4 mL/min.
    • Calculating Dose in Milliliters (mL) and Number of Vials Required
      • Patient dose volume in mL:
        • Body weight in kg multiplied by 3 = dose in mL - The multiplication factor 3 represents the per kilogram dose (6 × 1013 vg/kg) divided by the amount of vector genomes per mL of the ROCTAVIAN suspension (2 × 1013 vg/mL).
      • Number of Roctavian vials to be thawed:
        • Patient dose volume (mL) divided by 8 = number of vials to be thawed (round up to next whole number of vials) - The division factor 8 represents the minimum volume of ROCTAVIAN extractable from a vial (8 mL).
  • Example of Dose Volume and Number of Vials to be Thawed

  • Roctavian can be administered only once.
Coverage Duration:
  • 1 Time Authorization in Lifetime
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • The incidence rate of inhibitor development in patients with hemophilia A who have been previously treated for at least 150 EDs has been estimated to be approximately 2–5 per 1000 patient-years. 
  • About 20% of the people with Hemophilia A in U.S are estimated to produce antibodies, which could make the ineligible for the AAV5-mediated gene therapy.
Policy Updates:
  • 11/14/2023 – New policy approved by P&T.
References:
  1. Pasi K.J., Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAv5-hFVIII-SQ gene therapy for hemophilia A. New Eng J of Med. 2020;382:29-40.
  2. Rangarajan S, Walsh L, Lester W, et al. AAV5–factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017;377:2519-30. 
  3. Hermans C, Astermark J, de Moerloose P. Exposure to factor VIII and prediction of inhibitor development: exposure days vs.danger days, or both?J Thromb Haemost 2012;10:2194.
  4. Biomarin's Valrox, possible 1st gene therapy for hemophilia A, Under FDA priority review. Hemophilia News Today; February 2020. Available at: https://hemophilianewstoday.com/2020/02/24/biomarins-valrox-possible-first-gene-therapy-hemophila-a-under-fda-priority-review-marketing-application-accepted/
  5. Per clinical consult with hematologist, May 29, 2020. 
  6. Roctavian Prescribing Information. BioMarin Pharmaceutical Inc. Novato, CA. June 2023.

Last review date: December 1, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone